Lilly diabetes and obesity "transformative" new drugs will become the best-selling drugs in history! Sales will exceed $25 billion
Time of Update: 2022-10-14
5 percent in pre-market trading on Thursday after raising Eli Lilly shares from neutral to buy, and UBS analyst Colin Bristow said the company's newly approved type II diabetes drug, Mounjaro (Tirzepatide), could be "the best-selling drug of all time.
Good cooperation practice in food and drug supervision leads colleges and universities
Time of Update: 2022-09-18
On the morning of June 3, Li Jian, deputy secretary of the Party branch of the School of Pharmacy, Zhengzhou Railway Vocational and Technical College, led 17 fresh graduates of the school's food and drug majors to the Zhengdong New District Food and Drug Administration for a six-month off-campus theory-practice study teaching practice activities .
Luye Pharma's innovative formulation of goserelin microspheres for new breast cancer indications has been accepted for marketing application
Time of Update: 2022-08-19
62em; font-family:"Arial"; color:black; margin:0in; } SHANGHAI, Aug. 15, 2022 /PRNewswire/ -- Luye Pharma Group announced that its new drug candidate, Goserelin Acetate Sustained-Release Microspheres for Injection (LY01005) for the treatment of breast cancer, has been approved for marketing in China.
Junshi VV116 Phase III Clinical Treatment for Moderate and Severe COVID-19 Patients Completed the First Patient Dosing
Time of Update: 2022-05-27
On March 16, Junshi Biology announced that the oral nucleoside anti-SARS-CoV2 drug VV116 tablets jointly developed by the company's holding subsidiary Juntuo Biotechnology and Wangshan Wangshui has recently launched a study on the treatment of moderate to severe new coronaviruses.
[Nature] A research team from Cornell University and UBC has discovered a substance that can fight all virus variants, which may become the latest solution to the new crown
Time of Update: 2022-04-28
The researchers emphasized that the continued need for new coronavirus treatment options, especially the emergence of new sub-variants leading to a resurgence of cases, means that the pandemic "remains a significant threat to global health for the foreseeable future .
Isn't the risk of drug co-production quality related to the residue content and activity
Time of Update: 2021-12-07
If it is difficult to clean, it is easy to have the residue of the previous batch of materials, which will become an impurity in the next product .
Dongyang Sunshine GLP-1/FGF21 dual agonist HEC88473 injection was approved for clinical use
Time of Update: 2021-04-24
HEC88473 is the first GLP-1/FGF21 dual agonist approved for clinical use in China.
GLP-1/FGF21 dual agonist is expected to produce synergistic effects on blood sugar and weight loss.
New drug for primary IgA nephropathy
Time of Update: 2021-03-17
com" target="_blank">/ --Swedish biopharmaceutical company Calliditas Therapeutics recently announced that it has submitted a new drug application (NDA) for Nefecon (budesonide) to the U.
com/fda/" target="_blank">FDA Nefecon will be the first therapy specifically designed and approved for the treatment of IgAN.
Osaikang forced Hengrui to take the second of 2 billion anti-tumor drugs
Time of Update: 2021-01-23
Table 1: Currently reviewed tymoamine-related products Source: Minet MED2.0 China Drug Review Database Currently in the domestic market, tymoamine capsules and injections have been approved for listing, capsule evaluation enterprises There is Tianshili, Shuangli Pharmaceuticals, and has been included in the fourth batch of national collection catalog, will be the original study of Merca East to start a price war, and injections in addition to Hengrui Medicine, Osaikang also according to the new classification was approved as a review.
The new fusion protein therapy is expected to treat clotting disorders
Time of Update: 2021-01-05
researchers have developed an experimental fusion protein called BIVV001, which has not been shown to stop haemophilia patients from bleeding in a large-scale clinical trial, but it can prolong the clotting factor, much to the excitement of some researchers.
How is the global new crown vaccination progressing under the "cold winter" of the epidemic
Time of Update: 2020-12-24
; the German government said earlier this month that all vaccination centres in the German states would be in place by mid-December, and that Germany was expected to be able to vaccinate the first batch of high-risk populations and health care workers in January.
The State Drug Administration issued an announcement on the revision of the instructions for the injection of birdine in mendionine
Time of Update: 2020-11-10
The specific announcement is as follows: The State Drug Administration's announcement on the revision of the instruction manual for the injection of mentamate birdine (No. 121 of 2020) in order to further ensure the safety of public drug use, the State Drug Administration decided to the mendionine birdine injection (Including mentatinine birdine injection, injection of methionine birdine) instruction manual "adverse reactions", "precautions", "taboos", "pregnant and lactating women medication", "children's medicine", "old age medication" items are revised.
FDA approves Roche Polivy for recurrent or incurable diffuse large B-cell lymphoma
Time of Update: 2020-06-02
On Monday, the U.S FDA approved Roche Polivy (formerly known as polatuzumab), in combination with rituximaandiandand and chemotherapy benzodiazepines, for patients with diffuse large B-cell lymphoma w
PD-1 like fire cooking oil Who is the next potential target
Time of Update: 2020-05-20
On May 7, Cinda Biopharma and Lilly Pharmaceuticals jointly announced that the pD-1 immunosuppressant Damershu (Sindili monoantigen) combined with cadubolimono injections and platinum chemotherapy fir
Baiyunshan 3.1 new drug gefitinib API accepted
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on August 4, the class 3.1 new drug gefitinib API declared by Baiyunshan was accepted At present, only the original research d